 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Centre for Integrated Health Programs LTD/GTE |
| Street 1: | Plot 1129, Kikuyu Close, Off Nairobi Street, Wuse 2 |
| Street 2: | |
| City: | Abuja |
| Province: | Does Not Apply |
| Post Code: | 900288 |
| Country: | Nigeria |
| Phone: | 09112225111 |
| Organization Email: | info@cihpng.org |
| Web Site: | http://cihpng.org/ |
| Other Online Presence: | instagram: @cihpng |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | RC890766 |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Community-Based Organization (CBO) |
| Organization Description: | |
| The Centre for Integrated Health Programs (CIHP) is a non-governmental, not-for-profit organization with over 13 years supporting quality public health programs in Nigeria. Our vison is to transform lives through partnerships for improved health and development outcomes. Our Mission: We are a team of committed individuals using our collective learnings and experiences, innovativeness and passion for excellence to deliver equitable, quality, cost effective and integrated health interventions through sustainable partnerships. We are interested in tuberculosis because it aligns with our strategic goals as an organization which is to transform lives through health development. A quarter of the world’s population are infected with Tuberculosis. Tuberculosis is among the top 10 causes of death worldwide. Nigeria has the highest Tuberculosis burden in Africa and sixth burden globally, contributing 4.6% of the global TB burden with an incidence rate of approximately 219 per 100,000 population. Every hour, 15 Nigerians die from TB. Nigeria also has a high triple burden of TB, Drug Resistant Tuberculosis (DR-TB) and HIV-associated TB, and is one of the 10 countries that contribute the highest number of missing TB cases globally. In 2021, the National TB, Leprosy and Buruli Ulcer Control Program (NTBLCP) documented a gap of 56% of the estimated cases unidentified with 80% of DR-TB cases still missing. Only about 1 in 10 children with TB were found in 2021. A 69% funding gap further contributes to widening these gaps in ending the TB epidemic in Nigeria. CIHP is dedicated to combating tuberculosis through comprehensive and locally adaptable solutions, innovative research, and community engagement in line with the UNOPS ENDTB strategy as well as the strategic approaches outlined in the National Strategic Plan (NSP) 2021-2025. CIHP deploys a multidisciplinary and multisectoral approach to implementation of its TB only or TB/HIV integrated activities. | |
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Delivery of health services and care Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 26 - 50 |
| Number of volunteers who are directly involved with TB: | 51 - 99 |
| How did you hear about the Stop TB Partnership: | Other partners |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | Nigeria |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| The Centre for Integrated Health Programs (CIHP) is a member of the M&E Technical Working Group (TWG) that was inaugurated in November 2011 by the National Coordinator, of the National TB and Leprosy Control Program (NTBLCP). CIHP is incorporated in the National Tuberculosis Strategic Plan for 2021-2025 and contributes to both the planning and implementation phases of the mid-term reviews. CIHP functions as part of the National Advocacy Communication and Social Mobilization (ACSM) and a Technical Working Group (TWG) member. CIHP is a member of the Drug Resistance Tuberculosis Survey Protocol review team. CIHP attends and participates in the annual review meetings with other stakeholders for the National Tuberculosis and Leprosy Control Program. CIHP is a member of the National Tuberculosis Preventive Therapy Surge as Implementing Partners-HIV technical partners. CIHP supports the National Testing Week for Tuberculosis (both for children and the general population). |
|
Geographical Reach | |
| Which country is your headquarters located in: | Nigeria |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Nigeria |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: CIHP collaborates annually with the NTBLCP to implement key advocacy, communication, and social mobilization (ACSM) activities, including the commemoration of World TB Day (March 24th), National TB Testing Week (as communicated by NTBLCP), and National Childhood TB Testing Week (the week of May 27th). These joint efforts aim to raise awareness about TB, strengthen collaborative efforts towards TB screening, diagnosis, treatment, and contact tracing. By leveraging community engagement, media campaigns, and local partnerships, CIHP and NTBLCP work together to reduce TB stigma, improve access to services, and ensure that vulnerable populations are reached. Through these efforts, we continue to advance our shared global goal of ending TB. In line with PEPFAR strategic guidance, CIHP routinely develops and disseminates Information Education and Communication (IEC) materials on WHO 4 Screening Symptoms (W4SS) algorithm for screening childhood and adult TB, TB Infection Prevention and Control (IPC) and TB Preventive Therapy (TPT) to supported facilities and community based organizations (CBOs). Drug-Resistant TB: As a sub-recipient to IHVN under the TB LON3 grant in Osun State, CIHP provides vital technical support for identifying and treating drug-resistant TB (DR-TB) cases, contributing to the global efforts aimed at improving DR-TB case notification and ensuring effective treatment. By strengthening local diagnostic capabilities, enhancing case management, and supporting treatment adherence, CIHP helps to improve DR-TB outcomes and aligns with global strategies to detect and treat DR-TB early. These efforts contribute to the World Health Organization's goal of increasing global DR-TB case notification rates and reducing the burden of drug-resistant TB, advancing the global fight towards ending TB by 2035. TB-HIV: Over the past 13 years, CIHP under various projects in collaboration with the CDC has and continues to intensify active TB case finding and HIV testing across supported states in Nigeria. A core strategy involves actively screening all new and returning PLHIV for TB using the WHO 4 Signs and Symptoms (W4SS) checklist at each clinical visit. Healthcare workers at various service delivery points, including OPDs, HTS units, pediatrics, PMTCT, and medical wards, are mentored on the integration of TB services, with a focus on fast-tracking presumptive TB cases to DOTS for diagnostic workup, evaluation, and treatment. In addition to the W4SS checklist, CIHP uses other WHO-recommended screening tools such as chest X-rays, LF LAM urine analysis for advanced HIV clients (CD4<200), and Molecular WHO rapid diagnostics like GeneXpert and Truenat, to enhance sensitivity and ensure early detection. Through these efforts, CIHP is screening thousands of clients for TB, ensuring that all presumptive cases are promptly evaluated. The goal is to identify and treat all TB cases among PLHIV, and ensure that ART is initiated for all newly diagnosed TB-HIV co-infected patients, in alignment with global TB and HIV control strategies. HTS services are being strengthened across TB treatment units by ensuring that HIV testing is routinely offered for all presumptive, confirmed, and relapsed TB cases, as well as their contacts at DOTS sites. Additionally, referral linkages between TB treatment units and ART clinics are being reinforced to ensure seamless care and ART initiation for all newly diagnosed TB-HIV co-infected individuals. Through the One Stop Shop (OSS) integration model, TB/HIV co-infected clients receive streamlined and holistic care across both TB and HIV services. CIHP is also actively supporting community TB case finding in partnership with CBOs and state TB programs, reaching key populations who may otherwise be missed. TB contact investigations are carried out in households of index TB cases, with the support of CBO partners. To ensure quality care, clinicians’ capacity for TB diagnosis is regularly built through on-site mentoring and virtual support. TB diagnosis and HTS activities are closely monitored on a weekly basis to track progress, identify gaps, and drive continuous improvements in service delivery. Through these ongoing activities, CIHP remains committed to increasing TB case detection among PLHIV, ensuring timely treatment, and contributing to the global efforts to reduce TB and HIV co-infection while also contributing to the World Health Organization's End TB Strategy and UNAIDS 95-95-95 goals. These initiatives are essential in accelerating TB diagnosis, improving treatment adherence, and preventing further TB transmission among HIV-positive populations. By prioritizing early detection, timely treatment, and integrated care, CIHP continues to play a pivotal role in advancing the fight against TB and HIV, ultimately working towards the global vision of a TB-free world by 2035. Laboratory Strengthening: CIHP strengthens laboratory systems through the optimization of GeneXpert sites for the efficient diagnosis and evaluation of TB. This effort is part of our broader strategy to enhance TB-HIV service integration. Additionally, CIHP has procured electronic fluorescence microscopes, along with essential accessories, refrigerators, and ancillary commodities, to establish a robust TB treatment monitoring system. This infrastructure is critical for improving the accuracy and timeliness of TB diagnosis and treatment monitoring while also focusing on building the capacity of Medical Laboratory Scientists who provide direct, quality laboratory services at CIHP-supported facilities and Key Population (KP) One Stop Shops (OSS). These initiatives ensure the effective integration of TB and HIV services, enhancing the overall quality of care and improving patient outcomes across the supported laboratories. New Diagnostics: In line with the TB/HIV Acceleration Plan, CIHP supported the procurement of Portable Digital X-ray (PDX) systems to support intensified TB case finding across PEPFAR Nigeria-supported sites and directly contributes to improving access to point-of-care (POC) diagnostics. The PDX system overcomes the limitations of traditional chest X-rays by offering enhanced mobility and accessibility, enabling high-quality imaging in remote and underserved settings. By reducing turnaround times for imaging and results, the PDX system facilitates faster clinical decision-making, ensuring timely diagnosis and treatment initiation. This approach aligns with the End TB Strategy by improving the accessibility and quality of TB diagnostics, particularly in hard-to-reach populations, and accelerating case detection. It also helps address the broader healthcare goal of reducing diagnostic delays, improving patient satisfaction, and reducing healthcare disparities. By strengthening POC diagnostic capabilities, the PDX system plays a pivotal role in achieving the global goal of ending TB, enhancing the integration of TB and HIV services, and ensuring more equitable access to care. New TB Drugs: CIHP successfully increased access to the new 3HP TPT regimen for qualified PLHIV across supported facilities and community-based organizations (CBOs). Regular TPT drives were conducted, and healthcare workers (HCWs) were equipped with updated job aids reflecting the latest guidelines. CIHP collaborated with NTBLCP and other partners to develop a TPT training module and conducted virtual orientations with CDC to ensure proper implementation of 3HP. TPT talking points were distributed, and TPT stickers were provided to help identify and track eligible clients. CIHP also created and shared line lists of clients who had missed TPT initiation, while weekly tracking through RADET ensured timely initiation of 3HP. To improve adherence, TPT monitoring was integrated into virtual treatment call logs, and follow-up calls were made to support clients. As a result, over 24,165 clients were initiated on TPT, including 2,213 clients on 3HP, with a 99% completion rate among both pediatric and adult clients. These efforts contributed to enhanced TB prevention and care, particularly for PLHIV, and supported the broader goal of increasing access to preventive TB treatment. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | September 10, 2024 |
| Last updated: | November 20, 2024 |